Sperm DNA Fragmentation

Decision tree across top clinics for Adam’s not-yet-done DNA fragmentation test.

Last updated: Apr 28, 2026 12:21 AM PT
Why this matters: Adam hasn’t done a DNA fragmentation test yet (not offered at Grace Fertility). Previous IVF had decent fertilization (6/7 eggs fertilized) but no blastocysts — could be egg-side, sperm-side, or both. A €100–209 test removes one big unknown before we commit to 3 cycles. All four doctors we consulted had different takes: some said it’s essential, one said Adam’s sample looks too strong to bother.

Doctor Guidance at a Glance

Clinic Doctor’s position on testing Test cost / logistics
IVF Cube Dr. Stasna: NOT needed. “Adam’s sample is enormous” (strong numbers, no smoking, no harmful work exposure). Available if we want it. Not quoted. Microfluidic sorting is standard regardless.
ReproGenesis Dr. Maderka: Recommended. Routinely advises it after an IVF failure cycle. “Only way to know with high probability if we need a sperm-selection method.” Done at clinic on arrival, few days turnaround. Cost not quoted; expect ~€100 (ask Hana).
Repromeda Adéla offered it as Diagnostic SpermPacket add-on — not pushed as essential but readily available. €209 for the bundle (DNA fragmentation + Oxidative stress + Immasperm maturity). Richer than single-test peers.
Reprofit (reference) Dr. Kamil: Recommended. Doesn’t expect bad results given healthy natural son, but wants it for protocol finalization. 2–3 week turnaround — slowest of the four. Cost not quoted; expect ~€150.

Scenario 1 — Test done, result NORMAL

Each clinic uses their default sperm-handling approach. Per-cycle cost amortized across 3-cycle banking (includes DNA frag test cost, meds estimated at €2,000/cycle).

Clinic Default sperm method Per-cycle (banking) + Test cost Effective per-cycle
Repromeda (ICSI+PGT-A) Standard ICSI of all oocytes 5,445 +70 (209 ÷ 3) 5,515
IVF Cube Microfluidic (MFSS) standard in base 6,150 ~33 ~6,183
ReproGenesis Standard ICSI (no MFSS unless indicated) 6,705 ~33 ~6,738
Reprofit (ref) MFSS recommended by Dr. Kamil (+350/cyc) 7,257 +50 (150 ÷ 3) ~7,657 (w/ MFSS)

Repromeda wins on cost under normal result — skip the SpermPacket upgrade and keep basic ICSI+PGT-A.

Scenario 2 — Test done, result ELEVATED

Each clinic switches to (or intensifies) advanced sperm selection. Per-cycle uplift and cumulative 3-cycle delta shown.

Clinic Intervention Per-cycle uplift New per-cycle 3-cycle total delta
IVF Cube MFSS already standard — intensify with MACS or PICSI +450 ~6,633 +1,350
ReproGenesis Add ZymotChip (Dr. Maderka’s preferred method) +390 ~7,128 +1,170
Repromeda Upgrade: ICSI pkg → SpermPacket pkg
(MACS + ZymotChip + PICSI)
+375 (cyc 1)
+416 (cyc 2–3)
~5,890 +1,207
Reprofit (ref) MFSS already in dr rec; intensify with MACS +475 ~8,132 +1,425

3-cycle deltas are tight across the board (€1,170–1,425). Repromeda still cheapest overall, ZymotChip at ReproGenesis the cheapest per-cycle intervention.

Scenario 3 — Skip the test, start with clinic default

Save the test cost. Risk: if fragmentation is actually high, cycle 1 may produce poorer embryos — losing far more than the ~€200 we saved.

Clinic Default approach (no test) Per-cycle
IVF Cube MFSS standard — already covers moderate fragmentation 6,150
ReproGenesis Standard ICSI — if bad embryo results, regret skipping 6,705
Repromeda (ICSI+PGT-A) Standard ICSI — same regret risk as ReproGenesis 5,445
Reprofit (ref) MFSS by default on doctor rec 7,607

IVF Cube and Reprofit are the “safe to skip” options because they use advanced selection regardless. ReproGenesis and Repromeda only use it if indicated — skipping the test there is genuinely riskier.

Scenario 4 — Elevated + 3-month lifestyle intervention

Biology note: one sperm production cycle is ~74 days. Lifestyle changes (antioxidant supplements, reduced heat exposure, weight management, alcohol reduction) can measurably improve DNA fragmentation after ~3 months — but not sooner.

If the test comes back elevated in early May and we still start cycle 1 end of May, Adam hasn’t had time to intervene. The advanced sperm selection acts as a workaround for cycle 1. Cycles 2–3 (likely June–August) could benefit from improved baseline sperm if intervention happens concurrently.

Hybrid cost model

Probably not worth optimizing for unless results are severely elevated. But worth raising with the doctor in the planning conversation.

Other Scenarios to Consider

A. Severe fragmentation (>30% DFI)

May warrant TESA (testicular sperm aspiration) — bypasses ejaculated sperm entirely, uses testicular sperm which has lower DNA damage. All four clinics offer it. Adds ~€500–1,000 per cycle. Unlikely for Adam given healthy natural son 2 years ago.

B. Oxidative stress elevated (but DNA frag OK)

Repromeda’s €209 test detects this separately. Could indicate supplements (CoQ10, vitamin E, zinc) for 3 months rather than changing IVF approach. Other clinics don’t test for this by default.

C. Normal DNA frag, but poor fertilization in cycle 1

Would point to egg-activation issues rather than sperm. Different add-on: Oocyte Activation (calcium ionophore). Available at Repromeda (+€188) and Helios (+€130); others need to ask. Keep in mind if fertilization rate drops below ~60% in cycle 1.

D. Result delayed (esp. Reprofit’s 2–3 week turnaround)

If we pick Reprofit and don’t test until arrival, results may not return before retrieval. Have to commit to a sperm strategy blind. Mitigation: book the test in Budapest or Canada well ahead of travel, send results to whichever clinic we pick.

Bottom Line

Do the test. €100–209 is trivial against a €6K cycle. Removes a major unknown. Dr. Stasna’s “not needed” is based on sperm count, not fragmentation — and fragmentation can be elevated in men with normal counts.

Test cost estimates for IVF Cube, ReproGenesis, and Reprofit are market-rate approximations — none provided exact pricing on the consult call. Confirm with clinic before booking.

Per-cycle costs from ranking (3-cycle banking formula with meds €2,000/cyc). Advanced sperm selection add-on costs from pricing add-ons table.

Advanced sperm selection evidence is mixed. Cochrane reviews show low-certainty benefit for MACS, PICSI. ZymotChip/microfluidic has the most recent supportive evidence. All are plausible but none are slam-dunk.

↑ Back to top